Press Releases

Strengthens global intellectual property position with 13th issued patent covering the company's proprietary technology for the capture and detection of rare cells from biological fluids

Allowances extend Biocept's OncoCEE rare cell analysis microchannel patent coverage

Key Opinion Leaders to Advise on Expanding Adoption of Biocept's Liquid Biopsy Tests

Korean Patent Includes Microfluidic Channel for Capturing Circulating Tumor Cells

Fifth issued U.S. patent covers the use of antibodies in the capture and detection of rare cells from biological fluids with Biocept's microchannel capture device SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC) , a molecular diagnostics company commercializing and developing liquid

European patent covers the use of antibodies in the capture and detection of rare cells from biological fluids used in the company's liquid biopsy, or blood-based, molecular diagnostic assays

Biocept's c-MET Test Enables Physicians and Researchers to Identify Key Biomarker From Liquid Biopsy

Adds to Portfolio of Blood-Based 'Liquid Biopsies' With EGFR Mutation Identification to Assist Physicians With Treatment Decisions for Lung Cancer Patients

Proprietary platform enables local pathologists to participate in liquid biopsy testing with new capabilities to evaluate circulating tumor cells (CTCs) and expanded menu of biomarkers SAN DIEGO , March 13, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid

Target Selector™ molecular assay kits are research-use-only (RUO) and offer superior sensitivity compared to NGS-based biomarker analysis for the detection of key actionable oncogene mutations SAN DIEGO , May 14, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of